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Abstract 
Background: In Papua, Indonesia, maternal malaria is prevalent, multidrug resistant and associated with adverse 
outcomes for mother and baby. In March 2006, anti-malarial policy was revised for the second and third trimester of 
pregnancy to dihydroartemisinin–piperaquine (DHP) for all species of malaria. This study presents the temporal analy-
sis of adverse outcomes in pregnancy and early life following this policy change.
Methods: From April 2004 to May 2010, a standardized questionnaire was used to collect information from all preg-
nant women admitted to the maternity ward. A physical examination was performed on all live birth newborns. The 
relative risks (RR) and the associated population attributable risks (PAR) of adverse outcomes in women with a history 
of malaria treatment to the risk in those without a history of malaria during the current pregnancy were examined to 
evaluate the temporal trends before and after DHP deployment.
Results: Of 6,556 women enrolled with known pregnancy outcome, 1,018 (16%) reported prior anti-malarial treat-
ment during their pregnancy. The proportion of women with malaria reporting treatment with DHP rose from 0% 
in 2004 to 64% (121/189) in 2010. In those with history of malaria during pregnancy, the increasing use of DHP was 
associated with a 54% fall in the proportion of maternal malaria at delivery and a 98% decrease in congenital malaria 
(from 7.1% prior to 0.1% after policy change). Overall policy change to more effective treatment was associated with 
an absolute 2% reduction of maternal severe anaemia and absolute 4.5% decrease in low birth weight babies.
Conclusions: Introduction of highly effective treatment in pregnancy was associated with a reduction of maternal 
malaria at delivery and improved neonatal outcomes. Ensuring universal access to arteminisin combination therapy 
(ACT) in pregnancy in an area of multidrug resistance has potential to impact significantly on maternal and infant 
health.
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Background
In Papua Province, Indonesia, Plasmodium falciparum 
and Plasmodium vivax infections in pregnancy are asso-
ciated with adverse maternal and neonatal outcomes [1]. 
Malaria control in pregnancy in this region includes the 
use of long-lasting insecticide-treated nets (LLIN) and 
provision of early detection and prompt treatment with 
an effective anti-malarial drug. Prior to 2006 local guide-
lines recommended the use of sulfadoxine-pyrimeth-
amine (SP) and chloroquine (CQ) for uncomplicated 
malaria. However clinical trials highlighted high levels of 
resistance to both compounds [2]. Whilst quinine is an 
alternative treatment in pregnancy, prolonged treatment 
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regimens are required and these result in poor adher-
ence. Unsupervised seven-day courses of quinine in 
non-pregnant women are associated with more than 50% 
recurrent infections within 28 days [2]. Recurrent febrile 
illness in pregnancy has major adverse effects on both 
mother and foetus including maternal anaemia, low birth 
weight, miscarriage and perinatal mortality [3–5].
In view of the extremely poor efficacy of standard anti-
malarial treatment, the first-line treatment policy for 
uncomplicated malaria in Timika was changed in March 
2006 to dihydroartemisinin–piperaquine (DHP) for all 
species of malaria and in the second and third trimesters 
of pregnancy [2, 6]. Patients with severe malaria were 
treated with intravenous artesunate.
In this population a review of more than 1,000 preg-
nant women, treated with DHP highlighted its safety pro-
file and ability to reduce recurrent infections and malaria 
at delivery [3]. After more than 5 years of DHP deploy-
ment, the current study evaluates the temporal trends of 
maternal health and adverse pregnancy outcomes follow-
ing policy change.
Methods
Study site
Until November 2008 the Rumah Sakit Mitra Masyarakat 
(RSMM) was the only hospital in the Mimika district, 
servicing a population of approximately 2,00,000. This 
lowland region is largely forested with a climate that var-
ies little throughout the year. Rainfall in the lowlands is 
approximately 5,000 mm/year and varies little during the 
study period. Mean lowland temperatures are between 22 
and 32°C. Vector control programme in this region cov-
ers approximately 40% of the population.
The area has unstable malaria transmission which an 
estimated annual incidence of 876 per 1,000 person years, 
divided 60:40 between P. falciparum and P. vivax infec-
tions [7]. Treatment failures in this area are extremely 
high, with 65% having recurrent failure on day 28 after 
CQ monotherapy for P. vivax and 48% on day 42 after CQ 
plus SP for P. falciparum [2].
Study population
Each year there are approximately 3,000 pregnant women 
in Timika, of whom less than 40% attend antenatal care 
clinic [8]. Household surveys suggest that half of these 
women deliver at the RSMM hospital and the same pro-
portion sleep under insecticide-treated nets (ITN) (Mr. 
Usman, District Health Malaria Officer, personal com-
munication-2009). Intermittent presumptive treatment 
(IPT) for malaria is not available and HIV testing was not 
routinely carried out during the study period.
The ethnicity of the population includes lowland and 
highland Papuans, as well as non-Papuan ethnic groups 
attracted to the region by the local mine. In view of the 
high number of infections in non-immune patients, local 
protocols recommend that patients with parasitaemia 
detected by blood film examination irrespective of symp-
toms should be treated with anti-malarial drugs; this pol-
icy extends to pregnant women.
Study design
Data were derived from a hospital-based malaria surveil-
lance programme carried out between April 2004 and May 
2010. Following informed consent all pregnant women 
and newborn infants admitted to the maternity ward at 
RSMM hospital were enrolled into the study. The attend-
ing physician or research clinician prospectively reviewed 
all admissions. A systematic interview and review of the 
clinical notes was used to obtain data on maternal char-
acteristics, clinical condition (fever and signs of severity), 
history of possible malaria during the current pregnancy 
and its treatment, malaria treatment during hospitaliza-
tion, and birth outcome (Additional file  1). All newborn 
infants were weighed and a full physical examination was 
conducted by a trained research nurse. Gestational age 
was estimated using the New Ballard Score [9].
Maternal thick and thin blood films were obtained to 
assess peripheral parasitaemia. Parasite counts were 
determined from the number of parasites per 200 white 
blood cells (WBC) on Giemsa-stained thick films and 
considered negative after review of 200 high-power 
fields. A thin smear was also examined to confirm para-
site species and quantify parasitaemia if greater than 200 
parasites were visible per 200 WBC. Haemoglobin con-
centration was determined by electronic coulter counter 
(Coulter JT™, USA). Malaria was defined as the presence 
of peripheral asexual parasitaemia irrespective of clinical 
signs or species. Maternal anaemia was defined as severe 
if the haemoglobin was less than 7  g/dl [10]. Neonatal 
adverse outcomes (low birth weight, preterm delivery 
and perinatal deaths) were defined according to WHO 
criteria [11]. On admission to hospital, fever was diag-
nosed if women gave a history of fever within the pre-
ceding 24 h or had an axillary temperature greater than 
37.5°C.
Malaria was treated according to local protocols. Until 
March 2006 this was SP plus CQ for falciparum malaria 
and CQ alone for vivax malaria for the second and third 
trimesters of pregnancy. Quinine plus clindamycin was 
used for all species of malaria in the first trimester or 
when CQ and SP were not available. In March 2006 DHP 
became the recommended first-line treatment for uncom-
plicated malaria from any species of infection in the 
second and third trimester of pregnancy. Quinine and clin-
damycin were given in the first trimester. DHP (Artekin®, a 
fixed dose combination of 40 mg dihydroartemisinin and 
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320 mg piperaquine; Holley Pharmaceutical Co, PRC) was 
given according to the body weight with a target dose of 
2–4  mg/kg of dihydroartemisinin and 16–32  mg/kg of 
piperaquine, once a day for 3 days. Following the publica-
tion of a multicentre severe malaria treatment trial in 2005, 
which included patients recruited from Timika, intrave-
nous artesunate became the first-line treatment for severe 
malaria in pregnancy [12].
Statistical analysis
Data were entered into EpiData 3.02 software (EpiData 
Association, Odense, Denmark) and statistical analysis 
done using SPSS vs17.0 (SPSS Inc, Chicago, USA). Cat-
egorical data were compared by χ2 with Yates’ correction 
or by Fisher’s exact test. To control for potential tem-
poral changes in the patient demographics, the relative 
risk (RR) of adverse pregnancy outcomes were derived 
for women with history of malaria treatment compared 
to those without prior malaria during the same period. 
The period of analysis was divided into six blocks of 
12  months starting from April 2004 to May 2010, with 
March 2006 as the time when treatment policy changed.
The proportion of women with malaria during preg-
nancy and its associated RR were used to calculate the 
population attributable risk (PAR) of prior malaria dur-
ing pregnancy for each adverse outcome before and after 
policy change by using the following formula:
 The ratio of relative risks (RRR) between two relative 
risks and its significance was calculated according to the 
method of Altman and Bland [13]. The 95% confidence 
PAR :
proportion of population exposed × (RR− 1)
1+ [proportion of population exposed × (RR− 1)]
interval for PAR was calculated according to the delta 
method [14].
Previous studies have demonstrated that pregnant 
women with history of malaria in this region are at signif-
icantly greater risk of having malaria at delivery and other 
adverse pregnancy outcomes compared to women with-
out any history of malaria [1]. The impact of anti-malarial 
policy change will be most apparent in women treated for 
malaria during pregnancy, the magnitude of this impact 
dependent upon the proportion of women with malaria 
receiving the new treatment regimen. Therefore, overall 
temporal trends of the adverse outcomes were presented 
after stratifying by those with prior malaria illness.
In order to control for confounding factors in measur-
ing impact of malaria treatment policy change to mater-
nal and pregnancy outcomes, this study examined the 
seasonal variation in Mimika as well as the annual pro-
portion of primigravidae and pregnant women aged 
≤16 years old [1].
Ethical approval
Ethical approval for this study was obtained from the 
ethics committees of the National Institute of Health 
Research and Development, Ministry of Health, Indo-
nesia (KS.02.01.2.1.3431) and Menzies School of Health 
Research, Darwin, Australia (04/47).
Results
In total, 7,744 pregnant women were enrolled in the 
study. Of the 6,556 (85%) women with known pregnancy 
outcomes, 286 were excluded (283 with miscarriage and 
three women with missing data). Of the remaining 6,270 
pregnant women, 1,018 (16%) had a history of malaria 
treatment during the current pregnancy (Figure 1).
Figure 1 Study and analysis profile.
Page 4 of 9Poespoprodjo et al. Malar J  (2015) 14:272 
Over the duration of the study, the proportion of 
women delivering with a history of malaria and malaria 
treatment during pregnancy increased initially from 
10% (94/931) in 2004 to 21% (218/1,057) in year 4 
(April 2007–March 2008), p  <  0.001, before decreas-
ing to 14.6% (189/1,288) in year 6 (Figure 2). In women 
with a history of malaria treatment, the proportion 
receiving DHP rose from zero prior to policy change 
to 64% by the end of the study (Figure 2). The RR and 
the associated PAR of the adverse outcomes stratified 
by history of antenatal malaria treatment prior to and 
following treatment policy change are presented in 
Table 1.
There was no difference in the proportion of preg-
nant women who were primigravidae and aged less than 
16  years old during the observation period (Figure  3). 
Women with a history of malaria treatment were more 
likely to be younger (age ≤  16  years old) and first-time 
mothers compared to those without history of malaria ill-
ness: odds ratio of 1.5 (95% CI 1.02–2.2, p = 0.039) and 
1.2 (95% CI 1.1–1.4, p = 0.008), respectively.
Maternal adverse outcomes
There was a significant reduction in the prevalence of 
malaria at delivery following the introduction of DHP. 
In women with a history of prior malaria treatment, the 
Figure 2 Prior anti-malarial treatment during pregnancy in women delivering. Numbers above the pie charts are proportion of pregnant women 
with history of malaria treatment in that year.
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proportion with malaria at delivery declined from 57% 
(142/248) before DHP deployment to 26% (201/770) after 
policy change, p < 0.001 (Figure 4).
A similar pattern was noted in the prevalence of 
severe maternal anaemia (Figure  4), the risk of severe 
anaemia declining steadily over the 5 years of the study 
in both women with and without a history of malaria 
treatment. The proportion of women with severe 
anaemia declined from 10.5% (192/1,829) before DHP 
deployment to 7.2% (307/4,248) after policy change, 
p  <  0.001 (Figure  4). The RR associated with history 
of malaria during pregnancy changing from 1.7 (95% 
CI 1.3–2.4) prior to policy change to 1.4 (95% CI 1.1–
1.8) after policy change [RRR: 2.6 (95% CI 2.1–3.3), 
p < 0.001]. This equated to a change in PAR of 9% (95% 
CI 4–13%) pre- and 7% (95% CI 3–10%) post-policy 
change.
Adverse outcomes of the newborn
The proportion of low birth weight (LBW) babies born of 
mothers without a history of malaria was 14% (736/5,223) 
and did not change significantly over the study period. 
However in mothers with prior malaria treatment the 
prevalence of LBW fell significantly from 20% (50/244) in 
the first 2  years of the study, to 12% (23/188) in year 6, 
p =  0.03 (Figure  5). Prior to DHP deployment, the risk 
of LBW in women with a history of malaria treatment 
was 1.5 (95% CI 1.2–2.0) compared to 1.1 (95% CI 1–1.3) 
after policy change [RRR: 1.4 (95% CI 1–1.9), p = 0.05]. 
The PAR of LBW associated with prior malaria treatment 
decreased from 6.6% (95% CI 3–10%) to 2% (95% CI 0.1–
4%) following treatment policy change.
The prevalence of preterm delivery rose significantly 
prior to DHP deployment, but was followed by a decline 
after year 3 (Figure  5). Although these trends were 
Table 1 Adverse maternal and pregnancy outcomes before and after treatment policy change
Valid cases refer to presence of variables required for the analysis.
Adverse outcomes Women with  
history of malaria  
during pregnancy
Women without  
history of malaria  
during pregnancy
Relative risks  
(95% CI)
P value Population attributable 
risks % (95% CI)
March 2004–March 2006: before treatment policy change
 Maternal malaria: delivery, n/
valid cases (%)
142/246 (57.7) 199/1,592 (12.5) 4.6 (3.9–5.5) <0.001 34.5 (29.3–39.8)
  Primigravidae 56/91 (61.5) 70/490 (14.3) 4.3 (3.3–5.6) <0.001 30.5 (22.1–38.9)
  Multigravidae 86/155 (55.5) 129/1,099 (11.7) 4.7 (3.8–5.8) <0.001 33.1 (26.8–39.3)
 Maternal severe anaemia, n/
valid cases (%)
40/241 (16.6) 152/1,588 (9.6) 1.7 (1.3–2.4) <0.001 8.8 (4.4–13.4)
 Low birth weight, n/valid  
cases (%)
50/244 (20) 215/1,608 (13.4) 1.5 (1.2–2.0) 0.003 6.6 (3.2–10.0)
 Preterm delivery, n/valid  
cases (%)
27/225 (12) 110/1,503 (7.3) 1.6 (1.1–2.4) 0.015 7.8 (2.7–12.9)
 Perinatal deaths, n/valid  
cases (%)
11/248 (4.4) 41/1,619 (2.5) 1.75 (0.9–3.2) 0.1 9.1 (0.1–18)
 Congenital malaria, n/valid 
cases (%)
14/195 (7.1) 14/706 (1.9) 3.8 (1.8–8.2) <0.001 25.7 (3.5–48)
April 2006–May 2010: After treatment policy change
 Maternal malaria: delivery, n/
valid cases (%)
201/770 (26.1) 508/3,632 (13.9) 1.9 (1.6–2.2) <0.001 13 (10.3–15.9)
  Primigravidae 81/265 (30.6) 185/1,112 (16.6) 1.8 (1.5–2.3) <0.001 12.7 (7.9–17.5)
  Multigravidae 120/505 (23.8) 324/2,515 (12.9) 1.8 (1.5–2.2) <0.001 12.8 (9.3–16.3)
 Maternal severe anaemia, n/
valid cases (%)
70/738 (9.5) 237/3,510 (6.8) 1.4 (1.1–1.8) 0.01 6.6 (3.2–10.1)
 Low birth weight, n/valid  
cases (%)
123/764 (16.1) 521/3,615 (14.4) 1.1 (0.9–1.3) 0.23 2 (0.1–3.9)
 Preterm delivery, n/valid  
cases (%)
121/740 (16.4) 462/3,472 (13.3) 1.2 (1.0–1.5) 0.03 3.8 (1.8–5.8)
 Perinatal deaths, n/valid cases 
(%)
27/770 (3.5) 165/3,632 (4.5) 0.8 (0.5–1.2) 0.21 n/a
 Congenital malaria, n/valid 
cases (%)
1/743 (0.1) 6/3,543 (0.2) 0.8 (0.1–6.6) 0.21 n/a
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apparent in both women with and without a history of 
malaria, the change was greater in women with a his-
tory of malaria. The RR of prematurity associated with 
prior history of malaria fell from 1.6 [95% CI 1.1–2.4] to 
1.2 [95% CI 1–1.5] after policy change [RRR: 1.3 (95% CI 
0.9–2.1), p = 0.199], the PAR decreasing from 7.8% (95% 
CI 3–13%) to 3.8% (95% CI 2–6%).
Over the study period perinatal death was recorded in 
250 (4%) of the 6,273 women delivering. There was no 
significant change in the risk of perinatal death associ-
ated with prior anti-malarial treatment; overall approxi-
mately 4.3% (44/1,018) in women with history of malaria 
treatment versus 4% (206/5,252) in those women without 
prior anti-malarial exposure, p = 0.54.
After March 2006, the relative risk of maternal to foetal 
malaria transmission associated with history of malaria 
treatment declined from 3.8 (95% CI 1.8–8.2) to 0.8 (95% 
CI 0.1–6.6), p = 0.17.
Discussion
The local Ministry of Health revised the anti-malarial 
policy in Timika in March 2006, and since this time the 
public health care sector has knowingly treated more 
than 2,900 pregnant women with DHP. At the sentinel 
site at the RSMM the clinical research team have docu-
mented DHP administration to 765 women, and recorded 
deliveries in 847 women known to have been exposed to 
DHP during pregnancy [3]. In the current analysis this 
surveillance network is used to evaluate the impact of the 
policy change on adverse pregnancy and foetal outcomes 
at the hospital maternity ward.
This study documented an initial rise in the number 
of women delivering with history of malaria and malaria 
treatment during pregnancy from 11% (79/693) in 2004 
to 20% (208/1,026) in 2007. During this period com-
munity and entomology unpublished studies conducted 
in parallel also demonstrated a paradoxical transient 
increase in the number of malaria cases in the general 
population. This increase in malaria coincided with an 
El Nino year, with a rise in vector numbers and malaria 
cases noted across Indonesia in the national statistics. 
Unpublished evidence also suggests additional effects 
from a shift in treatment-seeking behaviour resulting 
in improved surveillance following DHP introduction. 
Despite the increased number of pregnant women pre-
senting with malaria after the introduction of DHP, no 
corresponding increased risk in adverse outcomes was 
observed.
The interpretation of temporal trends of malaria-
related morbidity is complex. Treatment, patient 
demographics and health-seeking behaviour of women 
presenting to the antenatal clinics vary over time. The 
preliminary analyses of the temporal data in this study 
were based on simple before-and-after comparisons 
and did not take into account the trajectory of trends 
nor the likely autocorrelation of the data. For these 
reasons, interpretation of the study findings requires 
caution.
Figure 3 The yearly proportion of primigravidae (red line) and pregnant women age ≤16 years old (black line). The pie chart above the figures 
denote the proportions of women with prior anti-malarial exposure: Quinine: red, DHP: light green, CQ ± SP: light blue, AAQ: purple, others: dark blue.
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In women with antenatal malaria, the introduction of 
DHP was correlated with a 50% reduction in the risk of 
peripheral parasitaemia at delivery from 57 to 26%. The 
RR of malaria at delivery associated with prior treat-
ment was 4.6 (95% CI 3.9–5.5) before policy change to 
1.9 (95% CI 1.6–2.2] after DHP deployment, p  <  0.001. 
The PAR of malaria at delivery was 34% (95% CI 29–40%) 
before March 2006 and 13% (95% CI 10–16%) thereafter. 
This figure shows that 21% of maternal malaria at deliv-
ery could be prevented by treatment policy change. The 
reduction in the maternal malaria prevalence associated 
with policy change was similar between primi and multi-
gravidae women.
The fall in the proportion of women with peripheral 
parasitaemia at delivery was associated with a dramatic 
reduction in the risk of congenital malaria from 3 to 0.2% 
[15]. Indeed, there have been no more congenital cases of 
malaria since October 2008.
There was a significant reduction in the RR of LBW 
and a non-significant fall in severe maternal anaemia 
associated with antenatal malaria. The corresponding 
PAR fell from 7 to 2% and 9 to 7%, respectively. LBW 
and severe maternal anaemia are associated with fre-
quent malaria episodes and the timing of infections 
[16], and it is likely that the reduction in these out-
comes is due in part at least, to a reduction in the risk 
of recurrent malaria. The effect however was modest 
and this may reflect the limited access of mothers in 
this region to effective anti-malarial treatment. Inad-
equate quality of antenatal care would also compromise 
the pregnancy and health outcomes of pregnant women 
with relapsing P. vivax infections, which accounts for a 
Figure 4 Maternal adverse outcomes in women with history of malaria treatment during pregnancy (blue line) and in those without history of 
malaria treatment (orange line). The pie chart above the figures denote the proportions of women with prior anti-malarial exposure: Quinine: red, 
DHP: light green, CQ ± SP: light blue, AAQ: purple, Others: dark blue. Numbers above the lines are RR (95% CI). Black arrow marks the start of policy 
change.
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third of maternal malaria in this area [1]. The introduc-
tion of DHP was associated with a slight reduction in 
the risk of preterm delivery, however an unexplained 
increased in the proportion of this adverse outcome 
before policy change confounds the interpretation of 
this observation.
This study has several limitations. Firstly, it was not 
possible to evaluate the overall programme impact in the 
community since this study used hospital-based surveil-
lance. Although 76% of women came to the hospital for 
delivery, selection bias and treatment-seeking behaviour 
remain potential confounders of the analysis. However, 
the condition was controlled by comparing the RR of 
adverse outcomes in women with and without a history 
of malaria treatment.
Secondly, a history of symptomatic malaria and anti-
malarial treatment during pregnancy was obtained by 
interview, a method that is subjected to recall bias. 
However, pregnant women in this region are very 
familiar with malaria symptoms and alternative anti-
malarial drugs. A systematic interview method and 
review of the clinical notes revealed that the history 
of malaria treatment could be cross-checked in almost 
50% of women with excellent concordance between 
reported drug history and that documented from the 
records. Unfortunately, the interview method did not 
gather information on possible asymptomatic and 
untreated malaria in pregnant women, and this is likely 
to have underestimated the effectiveness of treatment 
policy change.
The study highlights the potential benefits of improv-
ing maternal and pregnancy outcomes in women through 
the introduction of more efficacious anti-malarial treat-
ment regimens. However, the wider impact on health 
Figure 5 Adverse pregnancy outcomes in pregnant women with history of malaria treatment (blue line) and in those without history of malaria 
treatment (orange line). The pie chart above the figures denote the proportions of women with prior anti-malarial exposure: Quinine: red, DHP: light 
green, CQ ± SP: light blue, AAQ: purple, Others: dark blue. Numbers above the lines are RR (95% CI). Black arrow marks the start of policy change.
Page 9 of 9Poespoprodjo et al. Malar J  (2015) 14:272 
targets will require improvements in case management 
and prevention programmes of malaria in pregnancy as 
well as implementation of strategies to ensure the deliv-
ery of universal coverage [17, 18]. In Papua, even though 
malaria control programmes in pregnancy focus on pro-
viding early diagnosis and prompt treatment, in real-
ity this capacity is available in less than half of the local 
health facilities with limited public health impact [7]. The 
challenges in the prevention of malaria are similar, high-
lighted by an ITN distribution programme to pregnant 
women in Timika district, initiated in 2007, which has 
achieved only 50% coverage.
Conclusions
The deployment of DHP for malaria in the second and 
third trimesters of pregnancy was associated with a sig-
nificant decrease in adverse maternal and infant out-
comes. This study paves the way for scaling up both 
treatment and prevention programmes using arteminisin 
combination therapy. The latter will require identifying 
the most effective method of service delivery and trans-
lating research into practice (Additional file 1).
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